CW
SMMT icon

CreativeOne Wealth’s Summit Therapeutics SMMT Stock Holding History

CreativeOne Wealth’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,670
Closed -$248K – 1209
2025
Q2 		$248K Sell
11,670
-9,499
-45% -$217K 0.01% 991
2025
Q1 		$408K Buy
21,169
+974
+5% +$19.5K 0.01% 755
2024
Q4 		$360K Hold
20,195
– – 0.01% 808
2024
Q3 		$442K Buy
20,195
+8,595
+74% +$120K 0.02% 668
2024
Q2 		$90K Buy
+11,600
New +$62.7K ﹤0.01% 753

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

CreativeOne Wealth's SMMT Position: Q3 2025 in Review

CreativeOne Wealth sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 11,670 shares — an estimated $248K sold.

CreativeOne Wealth first reported a position in SMMT in Q2 2024 and held it in 5 quarters. The position peaked at $442K in Q3 2024. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • CreativeOne Wealth reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • CreativeOne Wealth sold 11,670 Summit Therapeutics shares in Q3 2025, an estimated $248K.
  • CreativeOne Wealth first reported a position in Summit Therapeutics in Q2 2024 and held it in 5 quarters.
  • CreativeOne Wealth's Summit Therapeutics position peaked at $442K in Q3 2024.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on CreativeOne Wealth's 13F filing for Q3 2025, filed 13 Nov 2025.